Vaccination with the long synthetic NY-ESO-179–108 peptide with a strong immune adjuvant generated substantial and long lasting CD8+ and CD4+ T-cell responses lasting at least one year in stage III/IV melanoma patients, permitting further development of this vaccine formulation for cancer immunotherapy [109]. Here, CD8A is linked to melanoma.